Stem cell industry's 'huge development' in Bay Area
By Stephanie M. Lee,
San Francisco Chronicle
| 08. 29. 2014
Almost three years after a Bay Area company shut down the world's first clinical trial of a therapy using embryonic stem cells, another local company is reviving the therapy.
The treatment drew international attention in 2010, when Geron in Menlo Park began testing it in patients with severe spinal cord injuries. But it scrapped the project a year later because of a lack of funds - a move seen as a major blow to the nascent field.
The therapy was then sold to Asterias Biotherapeutics, also in Menlo Park. On Wednesday, Asterias said it had gained regulatory permission to test whether the treatment, which is derived from human embryonic stem cells, helps heal patients with a different kind of spinal cord injury.
Observers saw the news as a promising advancement for research in stem cells, which have the unique ability to both reproduce themselves and become tissue- or organ-specific cells. That regenerative capability could be harnessed to treat intractable diseases and injuries, scientists believe. But no stem cell-based therapies have made it to market.
"It's a step in the right...
Related Articles
By Ali Breland, The Atlantic | 08.20.2024
“Joining us now is Steve Sailer, who I find to be incredibly interesting, and one of the most talented noticers,” Charlie Kirk said on his internet show in October. Kirk, the 30-year-old founder of Turning Point USA, a right-wing...
By Megan Agnew, The Times | 09.15.2024
Faith Hartley always wanted two girls — a blonde and a redhead. “I thought, I’ll have one that looks like me,” says Hartley, 35, smoothing her golden hair in the Los Angeles valley home she shares with her husband, Neil...
By Emily R. Klancher Merchant, Los Angeles Review of Books | 08.22.2024
IN THE Operation Varsity Blues scandal of 2019, 50 wealthy parents were charged with trying to get their children into elite universities through fraudulent means. The story dramatically demonstrated the lengths to which some parents will go to ensure their...
By Julia Brown, The Conversation | 08.16.2024
With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and...